Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author OKADA, Livia Samara dos Reis Rodrigues FMUSP-HC
OLIVEIRA, Claudia P. FMUSP-HC
STEFANO, Jose Tadeu FMUSP-HC
NOGUEIRA, Monize Aydar
SILVA, Ismael Dale Cotrim Guerreiro da
CORDEIRO, Fernanda Bertucce
ALVES, Venancio Avancini Ferreira FMUSP-HC
TORRINHAS, Raquel Susana FMUSP-HC
CARRILHO, Flair Jose FMUSP-HC
PURI, Puneet
WAITZBERG, Dan L. FMUSP-HC
dc.date.issued 2018
dc.identifier.citation CLINICAL NUTRITION, v.37, n.5, p.1474-1484, 2018
dc.identifier.issn 0261-5614
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/29464
dc.description.abstract Background & aims: Currently there is no FDA-approved therapy for nonalcoholic steatohepatitis (NASH). Increased n-6/n-3 polyunsaturated fatty acids (PUFA) ratio can induce endoplasmic reticulum (ER) stress and mitochondrial dysfunction that characterize NASH. Our recent study with n-3 PUFA showed improvement in individual histologic parameters like steatosis, ballooning and lobular inflammation. We hypothesized that n-3 PUFA therapy mediated improvement in histologic parameters is modulated by lipidomic and proteomic changes. Methods: We therefore evaluated hepatic proteomic and plasma lipidomic profiles before and after n-3 PUFA therapy in subjects with NASH. In a double-blind, randomized, placebo-controlled trial, patients with NASH received 6-month treatment with n-3 PUFA (0.945 g/day [64% alpha-linolenic (ALA), 21% eicosapentaenoic (EPA), and 16% docosahexaenoic (DHA) acids]). Paired liver biopsy and plasma collected before and after-n-3 PUFA therapy were assessed using mass spectrometry and gas chromatography for hepatic proteomics and plasma lipidomics. Data were matched to UniProt and LIPID MAPS database, respectively. Cytoscape software was used to analyze functional pathways. Twenty-seven NASH patients with paired liver histology and plasma before and after n-3 PUFA treatment were studied. Results: Treatment with n-3 PUFA significantly increased ALA, EPA, and glycerophospholipids, and decreased arachidonic acid (p < 0.05 for all). Further, proteomic markers of cell matrix, lipid metabolism, ER stress and cellular respiratory pathways were also modulated. Interestingly, these alterations reflected functional changes highly suggestive of decreased cellular lipotoxicity potential; reduced ER proteasome degradation of proteins and induction of chaperones; and a shift in cell energy homeostasis towards mitochondrial beta-oxidation. Conclusion: Six-month treatment with omega-3 PUFAs significantly improved hepatic proteomic and plasma lipidomic markers of lipogenesis, endoplasmic reticulum stress and mitochondrial functions in patients with NASH.
dc.description.sponsorship · Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2011/09234-9, 2013/03742-8]
dc.language.iso eng
dc.publisher CHURCHILL LIVINGSTONE
dc.relation.ispartof Clinical Nutrition
dc.rights restrictedAccess
dc.subject Omega-3 PUFA; NASH; Proteomic; Lipidomic; Mitochondrial dysfunction; Endoplasmic reticulum stress
dc.subject.other nonalcoholic fatty liver; endoplasmic-reticulum stress; binding protein; energy homeostasis; hepatic steatosis; disease; acid; steatohepatitis; cells; gene
dc.title Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight
dc.type article
dc.rights.holder Copyright CHURCHILL LIVINGSTONE
dc.description.group LIM/07
dc.description.group LIM/14
dc.description.group LIM/35
dc.identifier.doi 10.1016/j.clnu.2017.08.031
dc.identifier.pmid 29249532
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author OKADA, Livia Samara dos Reis Rodrigues:FM:
hcfmusp.author OLIVEIRA, Claudia P.:FM:MGT
hcfmusp.author STEFANO, Jose Tadeu:FM:
hcfmusp.author ALVES, Venancio Avancini Ferreira:FM:MPT
hcfmusp.author TORRINHAS, Raquel Susana:FM:MGT
hcfmusp.author CARRILHO, Flair Jose:FM:MGT
hcfmusp.author WAITZBERG, Dan L.:FM:MGT
hcfmusp.author.external · NOGUEIRA, Monize Aydar:Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM 07 LIM 35, Sao Paulo, Brazil
· SILVA, Ismael Dale Cotrim Guerreiro da:Sao Paulo Fed Univ, Dept Gynecol, Lab Mol Gynecol, Sao Paulo, SP, Brazil
· CORDEIRO, Fernanda Bertucce:Sao Paulo Fed Univ, Dept Surg, Div Urol, Human Reprod Sect, Sao Paulo, Brazil
· PURI, Puneet:Virginia Commonwealth Univ, Richmond, VA USA
hcfmusp.origem.id WOS:000447578700005
hcfmusp.origem.id 2-s2.0-85039435885
hcfmusp.publisher.city EDINBURGH
hcfmusp.publisher.country SCOTLAND
hcfmusp.relation.reference · Berlanga A, 2014, CLIN EXP GASTROENTER, V7, P221, DOI 10.2147/CEG.S62831
· Betz C, 2013, P NATL ACAD SCI USA, V110, P12526, DOI 10.1073/pnas.1302455110
· Bravo R, 2013, INT REV CEL MOL BIO, V301, P215, DOI 10.1016/B978-0-12-407704-1.00005-1
· Brunt EM, 2011, HEPATOLOGY, V53, P810, DOI 10.1002/hep.24127
· Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004
· Capanni M, 2006, ALIMENT PHARM THERAP, V23, P1143, DOI 10.1111/j.1365-2036.2006.02885.x
· Charlton M, 2009, HEPATOLOGY, V49, P1375, DOI 10.1002/hep.22927
· Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200
· Cheng LC, 2015, MOL CELL ENDOCRINOL, V412, P12, DOI 10.1016/j.mce.2015.04.025
· Christoffersen C, 2011, P NATL ACAD SCI USA, V108, P9613, DOI 10.1073/pnas.1103187108
· Dasarathy S, 2015, J CLIN GASTROENTEROL, V49, P137, DOI 10.1097/MCG.0000000000000099
· Guzman C, 2013, BBA-MOL CELL BIOL L, V1831, P803, DOI 10.1016/j.bbalip.2012.12.014
· Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
· Jump DB, 2008, CHEM PHYS LIPIDS, V153, P3, DOI 10.1016/j.chemphyslip.2008.02.007
· Kainu V, 2008, J BIOL CHEM, V283, P3676, DOI 10.1074/jbc.M709176200
· Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
· Bargut TCL, 2014, LIPIDS, V49, P431, DOI 10.1007/s11745-014-3892-9
· Ma DWL, 2004, FASEB J, V18, P1040, DOI 10.1096/fj.03-1430fje
· Masterton GS, 2010, ALIMENT PHARM THER, V31, P679, DOI 10.1111/j.1365-2036.2010.04230.x
· McPherson S, 2015, J HEPATOL, V62, P1148, DOI 10.1016/j.jhep.2014.11.034
· Muir K, 2013, CANCER RES, V73, P4722, DOI 10.1158/0008-5472.CAN-12-3797
· Nogueira MA, 2016, CLIN NUTR, V35, P578, DOI 10.1016/j.clnu.2015.05.001
· Pais R, 2013, J HEPATOL, V59, P550, DOI 10.1016/j.jhep.2013.04.027
· Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018
· Pfaffenbach KT, 2010, AM J PHYSIOL-ENDOC M, V298, pE1027, DOI 10.1152/ajpendo.00642.2009
· POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
· Puri P, 2007, HEPATOLOGY, V46, P1081, DOI 10.1002/hep.21763
· RUSINOL AE, 1994, J BIOL CHEM, V269, P27494
· Sanyal AJ, 2014, GASTROENTEROLOGY, V147, P377, DOI 10.1053/j.gastro.2014.04.046
· Tang HH, 2010, FEBS LETT, V584, P662, DOI 10.1016/j.febslet.2009.12.051
· Wang D, 2006, ENDOCRINOLOGY, V147, P943, DOI [10.1210/en.2006-0138, 10.1210/en.2005-0570]
· Wang GQ, 2005, HEPATOLOGY, V42, P871, DOI 10.1002/hep.20857
· Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840
· Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200
· Younossi ZM, 2008, OBES SURG, V18, P1430, DOI 10.1007/s11695-008-9506-y
· Younossi ZM, 2010, J PROTEOME RES, V9, P3218, DOI 10.1021/pr100069e
· Zhao JM, 2011, P NATL ACAD SCI USA, V108, P14246, DOI 10.1073/pnas.1018075108
dc.description.index MEDLINE
dc.identifier.eissn 1532-1983
hcfmusp.citation.scopus 9
hcfmusp.citation.wos 6
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Estados Unidos


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics